SK海力士将于十分钟后举行三季报电话会。

China's National Joint Drug Procurement Office on Oct. 26 revoked the national procurement winning status for letrozole tablets produced by Eugia Pharma Specialities Limited and gadoterate meglumine injection produced by JSC Farmak. The office said both applicants recently reported they could not continue to supply the products and, after supervisory interviews, still failed to meet medical institutions' demand. Eugia and its applicant Hangzhou Ketu Supply Chain Co. were placed on the violations list and barred from participating in national drug procurement for four years; JSC Farmak and its applicant Shanghai Liyi Pharmaceutical Technology Co. were likewise listed and barred for two years.

Nick Timiraos reports Fed Chair Kevin Warsh wants to stop previewing future policy, but many colleagues say the Fed must explain how it will react to economic shifts. Warsh has sought to reduce public remarks, yet most peers have not followed suit: the Wall Street Journal counts at least 59 speeches, interviews or other public comments by 16 officials with one year+ tenure in the post-September policy meeting quiet period, roughly matching about 54 a year earlier. Warsh’s effort to change Fed communication is ongoing and proving difficult. Officials cite two opposing shocks to the U.S. economy—an energy shock from the Middle East war and an AI-driven investment boom—and are uncertain which force to target or how large a policy response should be. Even a chair more willing to speak for the committee would likely struggle to reconcile views under current conditions.